Plant Comparison
Blessed Thistle vs Common coltsfoot
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Blessed Thistle and Common coltsfoot: both belong to the Asteraceae family; they share 3 indicated uses (arthritis / joint pain, inflammation (general), skin irritation); 1 pharmacological action in common.
Evidence face-off — shared uses
| Condition | Blessed Thistle | Common coltsfoot | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 2/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Hepatotoxic constituents that are the central safety concern for this plant; regulatory limits and PA-controlled/PA-reduced products exist specifically because of these compounds.
Demulcent polysaccharide contributing to the traditional soothing action on irritated airways.
Pharmacological Actions
Appetite stimulant for loss of appetite (approved use under German Commission E)
Bitter digestive / stomachic for indigestion and dyspepsia (stimulates saliva and gastric secretion)
Bitter digestive / stomachic for indigestion and dyspepsia (stimulates saliva and gastric secretion)
Traditional & Indicated Uses
Appetite stimulant for loss of appetite (approved use under German Commission E)
inferred from anti-inflammatory action
inferred from anticancer action
Bitter digestive / stomachic for indigestion and dyspepsia (stimulates saliva and gastric secretion)
inferred from antimicrobial action
inferred from anti-inflammatory action
Galactagogue to support breast-milk supply (traditional; no valid clinical-trial evidence)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from sedative action
Safety, Cautions & Contraindications
As a member of the daisy family (Asteraceae/ragweed), it can cause allergic reactions in sensitive people; high doses reportedly cause stomach cramps, nausea and vomiting.
Avoid during pregnancy because of a traditional uterine-stimulating reputation.
Although traditionally used to support milk supply, there is no scientifically valid clinical evidence for the galactagogue use.
Safety notes (contraindications, interactions, pregnancy/lactation notes, adverse effects, dose-duration cautions) Important: Coltsfoot naturally contains pyrrolizidine alkaloids (PAs)—plant chemicals that can damage the liver and may increase cancer risk with enough exposure (EMA, 2021; Kopp et al., 2020).
Because of this, European regulators set very strict limits for PA exposure from herbal products (EMA, 2021).
Many safety-focused herbal references recommend avoiding homemade/internal coltsfoot use, unless the product is specifically made to be PA-controlled / PA-reduced (EMA, 2021).
Avoid internal use if you are pregnant or breastfeeding, have liver disease, or for children—these groups are treated as “sensitive” in PA risk guidance (EMA, 2021).
Medication caution: if you take medicines that stress the liver (some prescription drugs can), it’s extra important to avoid unregulated PA exposure (general PA risk logic; consult a clinician) (EMA, 2021).
Topical use may still carry PA considerations; EMA discusses limits and recommends use only on intact skin for PA-containing products (EMA, 2021).
Duke (2002) provides clinical support (score 2) for coltsfoot's anti-inflammatory and expectorant effects, explaining its traditional use in bronchitis and coughs. However, the plant contains hepatotoxic pyrrolizidine alkaloids (PAs), and Duke notes a carcinogenic score (1) — a critical safety concern. Commission E has placed restrictions on coltsfoot use, recommending maximum internal use of 4–6 weeks per year and avoiding use in pregnancy, lactation, and in children under 12. Duke rates its overall safety as low (+) and emphasizes that preparations free of PAs are preferred (Duke, 2002).
External Ids
Botanical Description
Branching annual herb with a hairy, reddish, ridged stem and spiny, deeply lobed leaves with prominent pale veins. The flower heads are pale yellow, thistle-like, surrounded by a whorl of spiny, leaf-like bracts, giving the plant its 'spotted thistle' appearance.[4]
Low perennial herb notable for flowering before its leaves appear: solitary, bright yellow, dandelion-like flower heads emerge on scaly pinkish stalks in very early spring, followed later by large, hoof-shaped (heart-shaped with angular teeth), white-woolly-backed leaves arising directly from the creeping rhizome.[11]
Habitat
Grows on dry, sunny waste ground, roadsides and rocky slopes; native to the Mediterranean region and Western Asia and naturalised elsewhere as a garden escape.[4]
Grows on disturbed, damp or clay-rich waste ground, riverbanks, railway embankments and bare soil; native to Europe, North Africa and temperate Asia and naturalised in North America.[11]
Harvesting
The flowering aerial parts are cut as the plant comes into flower, in summer, and dried in a warm, shaded, airy place to preserve the bitter principle cnicin.[4]
Flowers are gathered in very early spring before the leaves appear; leaves are gathered later in the season once expanded. Given the plant's pyrrolizidine alkaloid content, harvesting from a positively confirmed patch (not a look-alike) and preferring PA-tested commercial material for internal use is strongly advised.[2]
Traditional Uses
Blessed thistle has a long European folk reputation as a bitter digestive tonic for loss of appetite and dyspepsia (an approved use under German Commission E) and, more anecdotally, as a traditional galactagogue to support breast-milk supply, though robust clinical evidence for the latter is lacking.[4, 11]
Coltsfoot has an ancient European and Chinese tradition, reflected in its Latin name (tussis = cough), as an expectorant and demulcent remedy for coughs, bronchitis and irritated airways; because of its pyrrolizidine alkaloid content, contemporary use is restricted to short courses of PA-controlled preparations under regulatory limits (see contraindications).[1, 2, 12]
Preparations
Dried flowering herb infused briefly in hot water as a bitter digestive tea, taken before meals.
Commercially prepared, pyrrolizidine-alkaloid-tested extract or syrup, the only form recommended for internal use given the plant's natural PA content.
Dried flower or leaf infused in hot water; traditional but subject to strict duration/PA-content limits under EU herbal regulation.
Dosage
Traditional herbal references suggest around 1-2 g of dried herb per cup, taken before meals, up to three times daily. Educational reference only, not a prescription.
EU regulatory guidance restricts internal use to PA-controlled preparations. The EMA public statement on unsaturated pyrrolizidine alkaloids records a maximum daily intake for internal use of 1 microgram of PAs for at most 6 weeks per year, or 0.1 microgram per day with no duration limit; for cutaneous use the limits are 100 micrograms for at most 6 weeks per year, or 10 micrograms without a duration limit. Not for use in pregnancy, breastfeeding, or children. Note that these are limits on PA intake, not a herb dose — no EMA monograph exists for Tussilago farfara, so there is no official posology for the herb itself. Educational reference only, not a prescription — consult a qualified practitioner and prefer tested commercial products.
References
Lookalikes Review
Dangerous Lookalikes
Not documented
References & Sources
- Rezig, K., Benkaci-Ali, F., Foucaunier, M.L., Laurent, S. et al (2023) 'HPLC/ESI-MS Characterization of Phenolic Compounds from Cnicus benedictus L. Roots: A Study of Antioxidant, Antibacterial, Anti-Inflammatory, and Anti-Alzheimer's Activity', Chemistry & Biodiversity, 21(1), pp. e202300724. doi:10.1002/cbdv.202300724 Preclinical
https://doi.org/10.1002/cbdv.202300724 - Ahmadimoghaddam, D., Sadeghian, R., Ranjbar, A., Izadidastenaei, Z. and Mohammadi, S (2020) 'Antinociceptive activity of Cnicus benedictus L. leaf extract: a mechanistic evaluation', Research in Pharmaceutical Sciences, 15(5), pp. 463-472. doi:10.4103/1735-5362.297849 Preclinical
https://doi.org/10.4103/1735-5362.297849 - Zhang, J., Shen, S., Zhu, S., Jia, F. et al (2024) 'Cnicus benedictus extract-loaded electrospun gelatin wound dressing for treating diabetic wounds: An in vitro and in vivo study', Journal of Applied Biomaterials & Functional Materials, 22, pp. 22808000241245298. doi:10.1177/22808000241245298 Preclinical
https://doi.org/10.1177/22808000241245298 - Zietal, K., Mirowska-Guzel, D., Nowaczyk, A. and Blecharz-Klin, K (2024) 'Cnicus benedictus: Folk Medicinal Uses, Biological Activities, and In Silico Screening of Main Phytochemical Constituents', Planta Medica. doi:10.1055/a-2401-6049 Traditional / reference
https://doi.org/10.1055/a-2401-6049 - Jalil, D.M., Al-Mahdawi, T.T., Jameel, M.G. and Talal, M (2024) 'In Vitro Evaluate the Antiproliferative Impact of Cnicus Benedictus L. Leaves Methanolic Extract on Cervical Cancer', Asian Pacific Journal of Cancer Prevention, 25(10), pp. 3643-3649. doi:10.31557/APJCP.2024.25.10.3643 Preclinical
https://doi.org/10.31557/APJCP.2024.25.10.3643 - Peng, Y., Jian, Y., Zulfiqar, A., Li, B., Zhang, K., Long, F., Peng, C., Cai, X., Khan, I.A. and Wang, W (2017) 'Two new sesquiterpene lactone glycosides from Cnicus benedictus', Natural Product Research, 31(19), pp. 2211-2217. doi:10.1080/14786419.2017.1295239 Preclinical
https://doi.org/10.1080/14786419.2017.1295239 - Paun, G., Neagu, E., Moroeanu, V., Albu, C., Savin, S. and Lucian Radu, G (2019) 'Chemical and Bioactivity Evaluation of Cnicus benedictus and Eryngium planum Polyphenolic-Rich Extracts', BioMed Research International, 2019, pp. 3692605. doi:10.1155/2019/3692605 Preclinical
https://doi.org/10.1155/2019/3692605 - Gobrecht, P., Gebel, J., Leibinger, M., Zeitler, C., Chen, Z., Grundemann, D. and Fischer, D (2024) 'Cnicin promotes functional nerve regeneration', Phytomedicine, 129, pp. 155641. doi:10.1016/j.phymed.2024.155641 Preclinical
https://doi.org/10.1016/j.phymed.2024.155641 - Avula, B., Katragunta, K., Wang, Y.H., Ali, Z. and Khan, I.A (2022) 'Simultaneous determination and characterization of flavonoids, sesquiterpene lactone, and other phenolics from Centaurea benedicta and dietary supplements using UHPLC-PDA-MS and LC-DAD-QToF', Journal of Pharmaceutical and Biomedical Analysis, 216, pp. 114806. doi:10.1016/j.jpba.2022.114806 Preclinical
https://doi.org/10.1016/j.jpba.2022.114806 - Paun, G., Neagu, E., Albu, C. and Radu, G.L (2015) 'Inhibitory potential of some Romanian medicinal plants against enzymes linked to neurodegenerative diseases and their antioxidant activity', Pharmacognosy Magazine, 11(Suppl 1), pp. S110-S116. doi:10.4103/0973-1296.157709 Preclinical
https://doi.org/10.4103/0973-1296.157709 - Drugs.com (n.d.) 'Blessed Thistle Uses, Benefits & Dosage'. Available at: https://www.drugs.com/npp/blessed-thistle.html Traditional / reference
https://www.drugs.com/npp/blessed-thistle.html - Drugs and Lactation Database (LactMed) (2021) 'Blessed Thistle'. Available at: https://www.ncbi.nlm.nih.gov/books/NBK501775/ Traditional / reference
https://www.ncbi.nlm.nih.gov/books/NBK501775/
- Ahmad, I., Kudaibergenova, B., Ahmad, M. and others (2025) 'Coltsfoot (Tussilago farfara L.; Asteraceae): modern methods of extraction, phytochemistry, nanoparticles synthesis, ethnopharmacology, and biological activities', Natural Product Research, pp. 1-20. doi:10.1080/14786419.2025.2548616 Traditional / reference
https://doi.org/10.1080/14786419.2025.2548616 - Chen, S., Dong, L., Quan, H., Zhou, X. and others (2020) 'A review of the ethnobotanical value, phytochemistry, pharmacology, toxicity and quality control of Tussilago farfara L. (coltsfoot)', Journal of Ethnopharmacology, 267, pp. 113478. doi:10.1016/j.jep.2020.113478 Traditional / reference
https://doi.org/10.1016/j.jep.2020.113478 - Feng, J., Zhang, Y., Qin, X., Gao, T. and others (2022) 'Novel Quinic Acid Glycerates from Tussilago farfara Inhibit Polypeptide GalNAc-Transferase', ChemBioChem, 23(3), pp. e202100539. doi:10.1002/cbic.202100539 Preclinical
https://doi.org/10.1002/cbic.202100539 - Zhao, J., Evangelopoulos, D., Bhakta, S., Gray, A.I. and Seidel, V (2014) 'Antitubercular activity of Arctium lappa and Tussilago farfara extracts and constituents', Journal of Ethnopharmacology, 155(1), pp. 796-800. doi:10.1016/j.jep.2014.06.034 Preclinical
https://doi.org/10.1016/j.jep.2014.06.034 - Avila, C., Breakspear, I., Hawrelak, J., Salmond, S. and Evans, S (2020) 'A systematic review and quality assessment of case reports of adverse events for borage (Borago officinalis), coltsfoot (Tussilago farfara) and comfrey (Symphytum officinale)', Fitoterapia, 142, pp. 104519. doi:10.1016/j.fitote.2020.104519 Meta-analysis / review
https://doi.org/10.1016/j.fitote.2020.104519 - Lee, J., Park, S., Kim, M.J., Kwon, S.J. and others (2019) 'Sesquiterpenoids from Tussilago farfara Flower Bud Extract for the Eco-Friendly Synthesis of Silver and Gold Nanoparticles Possessing Antibacterial and Anticancer Activities', Nanomaterials (Basel), 9(6), pp. 819. doi:10.3390/nano9060819 Preclinical
https://doi.org/10.3390/nano9060819 - Bota, V.B., Neamtu, A.A., Olah, N.K., Chiselita, O. and others (2022) 'A Comparative Analysis of the Anatomy, Phenolic Profile, and Antioxidant Capacity of Tussilago farfara L. Vegetative Organs', Plants (Basel), 11(13), pp. 1663. doi:10.3390/plants11131663 Preclinical
https://doi.org/10.3390/plants11131663 - Boucher, M.A., Cote, H., Pichette, A., Ripoll, L. and Legault, J (2020) 'Chemical composition and antibacterial activity of Tussilago farfara (L.) essential oil from Quebec, Canada', Natural Product Research, 34(4), pp. 545-548. doi:10.1080/14786419.2018.1489384 Preclinical
https://doi.org/10.1080/14786419.2018.1489384 - Li, Z.Y., Zhang, J., Zhang, Y.B., Yang, X.W. and others (2022) 'Polyhydroxylated eudesmane sesquiterpenoids and sesquiterpenoid glucoside from the flower buds of Tussilago farfara', Chinese Journal of Natural Medicines, 20(4), pp. 301-308. doi:10.1016/S1875-5364(21)60120-6 Preclinical
https://doi.org/10.1016/S1875-5364(21)60120-6 - Jang, H., Lee, J.W., Lee, C., Jin, Q. and others (2016) 'Sesquiterpenoids from Tussilago farfara inhibit LPS-induced nitric oxide production in macrophage RAW 264.7 cells', Archives of Pharmacal Research, 39(1), pp. 127-132. doi:10.1007/s12272-015-0667-7 Preclinical
https://doi.org/10.1007/s12272-015-0667-7 - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Westendorf, J., Czok, G., Marquardt, R., Nausner, M., Krauer, B. and Paul, H.L (1988) 'Pyrrolizidine alkaloid content of Tussilago farfara plants from different regions and preparations', pp. 903--909. Traditional / reference
https://scholar.google.com/scholar?q=Pyrrolizidine%20alkaloid%20content%20of%20Tussilago%20farfara%20plants%20from%20different%20regions%20and%20preparations - European Medicines Agency (HMPC) (2021) 'Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs), including recommendations regarding contamination of herbal medicinal products with PAs, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Sperl, W. and Stuppner, H. and Gassner, I. and Judmaier, W. and Dietze, O. and Vogel, W (1995) 'Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea', European Journal of Pediatrics, 154(2), pp. 112-6. doi:10.1007/BF01991912 Clinical study
https://doi.org/10.1007/BF01991912
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.